Previous 10 | Next 10 |
2024-04-02 07:37:07 ET More on Annovis Bio Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects Annovis And Alzheimer's Disease: The Best-Laid Plans Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Annovis...
Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced the publi...
2024-03-20 16:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-20 12:25:51 ET More on Mid-day movers & stocks. Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript Personalis Q4 2023 Earnings Preview XTI Aircraft that will merge with Inpixon gets Chinese patent for an aircraft Seeking Alpha’s Quant...
2024-03-20 09:50:03 ET More on Annovis Bio Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects Annovis And Alzheimer's Disease: The Best-Laid Plans Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Annovis...
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients wi...
2024-02-29 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’...
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients w...
2024-02-12 09:06:20 ET Summary A small sample of patient anecdotes on the internet suggest that buntanetap has some degree of underlying activity in Parkinson’s disease (PD). 24-38% of patient anecdotes report a noticeable/measurable improvement in Parkinson’s sympto...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food an...
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
2024-07-11 09:15:04 ET H.C. Wainwright analyst issues BUY recommendation for ANVS on July 11, 2024 07:54AM ET. The previous analyst recommendation was Buy. ANVS was trading at $12.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...